Skip to main content
SpringerLink
Log in

A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The standard treatment for peripheral T-cell lymphomas (PTCLs) is undetermined. We designed a CHOPE/G regimen (cyclophosphamide, pirarubicin, vincristine, prednisolone, and etoposide alternating with a gemcitabine-based regimen) as the first-line treatment of PTCLs and compared with CHOP (cyclophosphamide, pirarubicin, vincristine, and prednisolone) and CHOPE (CHOP plus etoposide) regimen to evaluate the optimal chemotherapy regimen.

Methods

116 previously untreated PTCL patients received CHOP (N = 46), CHOPE (N = 46), or CHOPE/G (N = 24) regimen at Peking University Cancer Hospital from 2009 to 2017 and were retrospectively analyzed.

Results

The overall response rates (ORRs) of the CHOP, CHOPE, and CHOPE/G groups were 82.6%, 76.1%, and 75.0% (p = 0.673), with complete response (CR) rates of 32.6%, 56.5%, and 45.7% (p = 0.063), respectively. Within a median follow-up time of 35.5 months, the 3-year overall survival (OS) rates of the CHOP, CHOPE, and CHOPE/G groups were 37.0%, 47.0%, and 56.3% (p = 0.107), and the 3-year progression-free survival (PFS) rates were 19.9%, 29.9%, and 5.3% (p = 0.093), respectively. Compared with the CHOP regimen alone, CHOPE had a significantly higher CR rate (p = 0.021) with more favorable OS (p = 0.046). The CHOPE/G regimen did not improve the ORR, CR rate, or OS compared with either the CHOP or CHOPE, with a significantly poorer PFS compared with the CHOPE regimen (p = 0.029). Anemia and thrombocytopenia occurred most frequently in the CHOPE/G group (anemia 83.3%, p = 0.035; thrombocytopenia 50%, p = 0.015).

Conclusions

Compared with CHOP alone, CHOPE regimen improved the efficacy and survival; while the addition of gemcitabine in the front-line therapy resulted in more adverse events without benefit of survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380(9844):848–857. https://doi.org/10.1016/S0140-6736(12)60605-9

    Article  PubMed  Google Scholar 

  2. Ascani S, Zinzani PL, Gherlinzoni F et al (1997) Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol 8(6):583–592. https://doi.org/10.1023/A:1008200307625

    Article  PubMed  CAS  Google Scholar 

  3. Morton LM, Wang SS, Devesa SS et al (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107(1):265–276. https://doi.org/10.1182/blood-2005-06-2508

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Chihara D, Ito H, Matsuda T et al (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536–545. https://doi.org/10.1111/bjh.12659

    Article  PubMed  Google Scholar 

  5. Park S, Ko YH (2014) Peripheral T cell lymphoma in Asia. Int J Hematol 99(3):227–239. https://doi.org/10.1007/s12185-014-1520-3

    Article  PubMed  CAS  Google Scholar 

  6. Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130. https://doi.org/10.1200/JCO.2008.16.4558

    Article  PubMed  Google Scholar 

  8. National Comprehensive Cancer Network (2018) Lymphomas T-Cell (Version 5) https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed 13 Aug 2018

  9. Ellin F, Landstrom J, Jerkeman M et al (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124(10):1570–1577. https://doi.org/10.1182/blood-2014-04-573089

    Article  PubMed  CAS  Google Scholar 

  10. Schmitz N, Trümper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin Lymphoma Study Group. Blood 116(18):3418–3425. https://doi.org/10.1182/blood-2010-02-270785

    Article  PubMed  CAS  Google Scholar 

  11. Nickelsen M, Ziepert M, Zeynalova S et al (2009) High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German high-grade non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20(12):1977–1984. https://doi.org/10.1093/annonc/mdp211

    Article  PubMed  CAS  Google Scholar 

  12. Escalón MP, Liu NS, Yang Y et al (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103:2091–2098. https://doi.org/10.1002/cncr.20999

    Article  PubMed  Google Scholar 

  13. Dunleavy K, Pittaluga S, Shovlin M et al (2016) Phase II trial of dose adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica 101:e27–e29. https://doi.org/10.3324/haematol.2015.131151

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Zinzani PL, Venturini F, Stefoni V et al (2010) Gemcitabine as single agent in pretreated T cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21(4):860–863. https://doi.org/10.1093/annonc/mdp508

    Article  PubMed  CAS  Google Scholar 

  15. Arkenau HT, Chong G, Cunningham D et al (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271–272. https://doi.org/10.3324/haematol.10737

    Article  PubMed  CAS  Google Scholar 

  16. Dong M, He XH, Liu P et al (2013) Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol 30(1):351. https://doi.org/10.1007/s12032-012-0351-4

    Article  PubMed  CAS  Google Scholar 

  17. Jia B, Hu S, Yang J et al (2016) Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. Hematology 21(9):536–541. https://doi.org/10.1080/10245332.2016

    Article  PubMed  CAS  Google Scholar 

  18. Kim JG, Sohn SK, Chae YS et al (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58(1):35–39. https://doi.org/10.1007/s00280-005-0136-y

    Article  PubMed  CAS  Google Scholar 

  19. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, Fourth edn. IARC WHO Classification of Tumours, No 2

  20. Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. https://doi.org/10.1200/JCO.2013.54.8800

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rüdiger T, Weisenburger DD, Anderson JR et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 13(1):140–149. https://doi.org/10.1093/annonc/mdf033

    Article  PubMed  Google Scholar 

  22. Xie W, Hu K, Xu F et al (2013) Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: a retrospective analysis of 252 cases. Mol Clin Oncol 1(5):911–917. https://doi.org/10.3892/mco.2013.146

    Article  PubMed  PubMed Central  Google Scholar 

  23. Mahadevan D, Unger JM, Spier CM et al (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119(2):371–379. https://doi.org/10.1002/cncr.27733

    Article  PubMed  CAS  Google Scholar 

  24. Gleeson M, Peckitt C, To YM et al (2018) CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol 5(5):e190–e200. https://doi.org/10.1016/S2352-3026(18)30039-5

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was funded by National Nature Science Foundation of China (Grant number 81470368 and Grant number 81670187), Beijing Natural Science Foundation (Grant number 7172047), Capital’s Funds for Health Improvement and Research (Grant number 2018-1-2151), Beijing Municipal Administration of Hospitals’ Ascent Plan (Grant number DFL20151001), and Beijing Medical and Health Foundation (Grant number 2221-16-157). We thank M.S. Lan Mi for statistical method supporting.

Funding

This study was funded by National Nature Science Foundation of China (Grant number 81470368 and grant number 81670187), Beijing Natural Science Foundation (Grant number 7172047), Capital’s Funds for Health Improvement and Research (Grant number 2018-1-2151), Beijing Municipal Administration of Hospitals’ Ascent Plan (Grant number DFL20151001), and Beijing Medical and Health Foundation (Grant number 2221-16-157).

Author information

Author notes

  1. Xuyan Liu and Mingzi Yang contributed to the work equally and should be regarded as co-first authors.

Authors and Affiliations

  1. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China

    Xuyan Liu, Mingzi Yang, Meng Wu, Wen Zheng, Yan Xie, Jun Zhu, Yuqin Song & Weiping Liu

Authors
  1. Xuyan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mingzi Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meng Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuqin Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Weiping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weiping Liu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Yang, M., Wu, M. et al. A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas. Cancer Chemother Pharmacol 83, 443–449 (2019). https://doi.org/10.1007/s00280-018-3744-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-018-3744-z

Keywords

Search

Navigation